UBS Group’s AC Immune ACIU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$15.2K Sell
7,467
-9,221
-55% -$18.7K ﹤0.01% 7310
2025
Q1
$31.2K Sell
16,688
-32,990
-66% -$61.7K ﹤0.01% 6623
2024
Q4
$134K Buy
49,678
+35,050
+240% +$94.6K ﹤0.01% 5483
2024
Q3
$55.3K Sell
14,628
-1,512
-9% -$5.72K ﹤0.01% 5552
2024
Q2
$64.4K Sell
16,140
-7,525
-32% -$30K ﹤0.01% 5345
2024
Q1
$70K Sell
23,665
-21,335
-47% -$63.2K ﹤0.01% 5204
2023
Q4
$225K Buy
45,000
+2,026
+5% +$10.1K ﹤0.01% 4538
2023
Q3
$122K Buy
42,974
+100
+0.2% +$285 ﹤0.01% 4589
2023
Q2
$127K Hold
42,874
﹤0.01% 4783
2023
Q1
$100K Hold
42,874
﹤0.01% 4841
2022
Q4
$87.5K Sell
42,874
-12,992
-23% -$26.5K ﹤0.01% 5101
2022
Q3
$176K Buy
55,866
+1,041
+2% +$3.28K ﹤0.01% 4175
2022
Q2
$198K Buy
54,825
+36,000
+191% +$130K ﹤0.01% 3944
2022
Q1
$75K Sell
18,825
-73,669
-80% -$294K ﹤0.01% 5101
2021
Q4
$457K Buy
92,494
+71,179
+334% +$352K ﹤0.01% 4044
2021
Q3
$143K Buy
21,315
+20,162
+1,749% +$135K ﹤0.01% 4509
2021
Q2
$10K Buy
1,153
+328
+40% +$2.85K ﹤0.01% 6922
2021
Q1
$6K Sell
825
-3,197
-79% -$23.3K ﹤0.01% 7180
2020
Q4
$21K Buy
4,022
+3,197
+388% +$16.7K ﹤0.01% 5894
2020
Q3
$4K Sell
825
-2,000
-71% -$9.7K ﹤0.01% 6498
2020
Q2
$19K Buy
2,825
+2,000
+242% +$13.5K ﹤0.01% 5737
2020
Q1
$6K Sell
825
-1,080
-57% -$7.86K ﹤0.01% 6287
2019
Q4
$16K Buy
1,905
+672
+55% +$5.64K ﹤0.01% 5948
2019
Q3
$6K Sell
1,233
-2,532
-67% -$12.3K ﹤0.01% 6417
2019
Q2
$21K Sell
3,765
-343
-8% -$1.91K ﹤0.01% 5702
2019
Q1
$21K Buy
4,108
+3,283
+398% +$16.8K ﹤0.01% 5432
2018
Q4
$8K Sell
825
-1,694
-67% -$16.4K ﹤0.01% 6405
2018
Q3
$21K Buy
+2,519
New +$21K ﹤0.01% 5851
2018
Q2
Sell
-2,119
Closed -$22K 6997
2018
Q1
$22K Buy
2,119
+2,057
+3,318% +$21.4K ﹤0.01% 5470
2017
Q4
$1K Buy
+62
New +$1K ﹤0.01% 6705
2017
Q3
Sell
-1,157
Closed -$10K 6752
2017
Q2
$10K Buy
+1,157
New +$10K ﹤0.01% 5818
2016
Q4
Sell
-1,537
Closed -$25K 6735
2016
Q3
$25K Buy
+1,537
New +$25K ﹤0.01% 5202